Meeting
2018 Gastrointestinal Cancers Symposium
Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3).
Authors
Jin Matsuyama
Yao Municipal Hospital, Yao, Japan
Jin Matsuyama , Yukinori Kurokawa , Kazuhiro Nishikawa , Yutaka Kimura , Atsushi Takeno , Junji Kawada , Ryohei Kawabata , Youichi Makari , Shigeyuki Tamura , Yuichiro Doki , Daisuke Sakai , Toshio Shimokawa , Taroh Satoh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000006179
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 119)
DOI
10.1200/JCO.2018.36.4_suppl.119
Abstract #
119
Poster Bd #
H23
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).
First Author: Izuma Nakayama
Poster
2017 ASCO Annual Meeting
Phase III study of individualized intraperitoneal/intravenous/oral chemotherapy compared with standard intravenous/oral chemotherapy in patients with advanced gastric cancer.
First Author: Yang Yang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
First Author: Hiroyuki Arai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07).
First Author: Hiroo Ishida